Abstract
Summary
Potassium iodide (KI) pretreatment; which has been reported to increase the clinical effectiveness of cyclophosphamide, increased the lethality of cyclophosphamide for mice. However, KI pretreatment failed to increase the experimental therapeutic effectiveness of cyclophosphamide for mice inoculated with LI210 leukemia. KI pre treatment also failed to alter hexobarbital sleeping times. There appears to be no significant synergistic action of KI on the therapeutic effects of cyclophosphamide investigated.
Get full access to this article
View all access options for this article.